FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma December 23, 2022January 20, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: European Commission approves Roche’s first-in-class…CHMP recommends EU conditional approval of Roche’s…FDA grants Priority Review to Roche’s Lunsumio for…FDA grants priority review to Roche’s bispecific…FDA accepts supplemental Biologics License…New pivotal data demonstrate clinical benefit of…
